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We are not suggesting that every test performed by an immunoassay be confirmed by a second independent technique. Clearly this is not needed or required in most clinical situations. Our point is that, whenever possible, all clinical assays should be validated by an independent technique before they are put into widespread use; this was the main focus of our original manuscript.
We compared the same extractionchromatography RIA assay (Quest Diagnostics, San Juan Capistrano, CA) referenced by Wians and Stuart with our negative chemical ionization (NCI) GC-MS method for female specimens. As shown in Fig. 1R , there was no statistically significant correlation between our GC-MS method and that used by the Quest Diagnostics (slope not significantly different from 0). Over the time period in which these samples were collected (2 months), our serum-based quality-control specimen (target value 0.72 nmol/L) averaged 0.75 nmol/L with a CV of 10% (n ϭ 9), demonstrating the accuracy and precision of the GC-MS method at low concentrations. The lack of correlation between our GC-MS method and the extraction-chromatography RIA is of concern and we are working with Quest Diagnostics to resolve the discrepancy.
The challenge faced by any immunoassay for the analysis of testosterone is a difficult one. The sample matrix is complex and known to contain many compounds structurally related to testosterone. The data presented by Wians and Stuart show that the ACS: 180 compares reasonably well with that of an extraction-chromatography RIA. However, agreement does not equal accuracy. Discrepancies between various methods will persist until a nationally or internationally recognized reference method for the analysis of testosterone is validated. We are actively pursing such a method, using isotope-dilution NCI GC-MS. 
Robert L. Fitzgerald* David A. Herold

Oxaprozin and 5-(p-Hydroxyphenyl)-5-phenylhydantoin Interference in Phenytoin Immunoassays
To the Editor: Rainey et al. [1] recently published their studies on metabolite and matrix interference in Abbott TDx ® Phenytoin (TDx) and Phenytoin-II (TDxII) assays (Abbott Labs., Abbott Park, IL). They report that TDx Phenytoin, which uses a polyclonal antibody, demonstrates a substantial positive bias in patients with renal insufficiency because of the assay's high (15.9%) cross-reactivity to the major metabolites of phenytoin, 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH) and its glucuronide ester (HPPG) [2] . They also report that the TDxII assay, which uses a monoclonal antibody, has high (ϳ50%) cross-reactivity to a nonsteroidal anti-inflammatory drug, oxaprozin (Daypro ® ) [1] .
During a recent study, a patient taking oxaprozin demonstrated discrepancy between phenytoin values by the TDxII, which gave the result in the toxic range, and that by Chiron Diagnostics' (Walpole, MA) new monoclonal assay, ACS:180 ® Phenytoin, for which the result was in the therapeutic range (GM Lawson, Mayo Clinic, personal communication).
To confirm the effects of oxaprozin in the TDx, TDxII, and ACS:180 Phenytoin assays, I studied the specificity of all three assays to oxaprozin and HPPH. Stock solutions of HPPH (Sigma Chemical Co., St. Louis, MO) and oxaprozin (Searle, Skokie, IL) in methanol were added to two separate serum pools, one containing phenytoin (pool B) and the other without phenytoin (pool A), and the apparent phenytoin concentrations were measured by all three assays according to the manufacturers' directions. The TDx assays were run on the TDxFlx ® analyzer, which uses homogeneous fluorescence polarization signals. The ACS:180 Phenytoin assay was run on the fully automated, random-access ACS:180 ® chemiluminescent system [3] .
The concentrations of the added cross-reacting compound and the observed phenytoin concentrations are presented in Table 1 . All three assays have comparable range (up to 40 mg/L) and detection limits (Ͻ1 mg/ L). The ACS:180 assay agreed well with both TDx and TDxII assays, demonstrating linear regression slopes of 1.02 and 0.94, intercepts of Ϫ1.46 and Ϫ0.19 mg/L, and correlation coefficients of 0.96 and 0.96, respectively, for 100 samples from patients taking phenytoin [4] .
These results for oxaprozin crossreactivity in TDxII agree with Rainey et al. (ϳ50%) [1] when oxaprozin is added to a phenytoin-free pool at 200 mg/L. At higher oxaprozin concentrations, however, the cross-reactivity is much higher (99% and 131% at 300 and 400 mg/L). Such cross-reactivity would result in seriously increased TDxII assay results in samples containing oxaprozin at 300 -400 mg/L. Although typical oxaprozin concentrations range from 98 to 230 mg/L [1] , there is a good likelihood of encountering patients with oxaprozin concentrations of 300 -400 mg/L. Our data also suggest that cross-reactivity in-creases when phenytoin is present in the sample. The respective apparent phenytoin concentrations are 101 and 121 mg/L in pools containing 0 or 9 mg/L of phenytoin when supplemented with 200 mg/L of oxaprozin. The TDx Phenytoin assay shows much lower cross-reactivity to oxaprozin (0.2-0.5%, depending on the concentrations of oxaprozin added) and is constant whether phenytoin is present in the sample or not. The ACS:180 assay shows no cross-reactivity to oxaprozin.
The data for HPPH cross-reactivity in the two TDx assays also agree with those of Rainey et al. Again, the cross-reactivity does not depend on the presence or absence of phenytoin (8.3% vs 6.8% in the TDx, and 9.2% vs 11.1% in the TDxII assay). The ACS:180 assay has insignificant (Ͻ1%) cross-reactivity to HPPH. No HPPG was available for comparing cross-reactivity to this compound in the assays described here.
In summary, 
